Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

BIA Life Science Leadership Summit

The BIA’s Life Science Leadership Summit gathers member CEOs for two days of insightful discussions and high-level networking in a stunning setting. Designed to support [...]

Go to Top